ERBB2 and breast carcinoma: Unfortunately, due to the lack of expression of hormone receptors and the absence of HER2 protein overexpression, there is currently no targeted therapy for this breast cancer subtype, and chemotherapy remains the standard treatment for patients with triple-negative disease.